RenovoRx (RNXT) Non-Current Assets (2020 - 2026)
RenovoRx (RNXT) posted Non-Current Assets of $244000.0 for Q1 2026, up 20.79% sequentially from $202000.0 in Q4 2025, and down 9.29% YoY from $269000.0 in Q1 2025.
RenovoRx (RNXT) Non-Current Assets (2020 - 2026) Analysis & Trends
RenovoRx has reported Non-Current Assets for 6 years, with the latest figure at $244000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 9.29% year-over-year to $244000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $920000.0 (up 64.58% YoY) and the FY2025 annual result came in at $202000.0, down 30.34% from the prior year.
- Non-Current Assets climbed to $244000.0 in Q1 2026 per RNXT's latest filing, from $202000.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $290000.0 in Q4 2024 and troughed at $3000.0 in Q1 2022.
- A 4-year average of $211714.3 and a median of $244000.0 in 2026 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets plunged 30.34% in 2025, then decreased 9.29% in 2026.
- Over 4 years, Non-Current Assets stood at $3000.0 in 2022, then jumped by 9566.67% to $290000.0 in 2024, then plunged by 30.34% to $202000.0 in 2025, then rose by 20.79% to $244000.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $244000.0, $202000.0, and $226000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 18.06 Bn |
| 10 | RenovoRx | 61.49 Mn | 61.49 Mn | 766,000.00 | 662,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 662,000.00 |
| Mar 31, 2026 | 244,000.00 |
| Dec 31, 2025 | 202,000.00 |
| Sep 30, 2025 | 226,000.00 |
| Jun 30, 2025 | 248,000.00 |
| Mar 31, 2025 | 269,000.00 |
| Dec 31, 2024 | 290,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Dec 31, 2021 | 6,000.00 |
| Sep 30, 2021 | 14,000.00 |
| Dec 31, 2020 | 4,000.00 |